PHIO: Phio Pharmaceuticals Corp Cash per Share

Corporate emblem and logo of Phio Pharmaceuticals Corp. (PHIO)

Phio Pharmaceuticals (PHIO) is expanding its oncology portfolio by suppressing tumor genes via RNA interference. This cash per share chart clearly demonstrates financial stability, where the 0.87 level captures the current state. This reinforces the pricing power of the INTASYL platform, which creates self-delivering RNA strands. The company is currently actively developing immuno-oncology products to enhance T-cells for the fight against cancer.

PHIO: Phio Pharmaceuticals Corp. Cash per Share 07/04/2022 - 11/20/2026

Comprehensive metric breakdowns and analytics for RXi Pharmaceuticals (PHIO)

- market price and analyst price targets:
- cash position and cash flow details:
Comprehensive company analysis:Phio Pharmaceuticals Corp
Signature product of Phio Pharmaceuticals Corp

Investors are assessing fundamental risks by analyzing available liquidity per unit of capital. For Phio Pharmaceuticals (PHIO), maintaining a cash reserve for the development of the INTASYL platform and the conduct of clinical trials is critical. The cash per share metric reflects the current volume of cash reserves distributed among all shareholders. A downward trend on this chart signals intensive capital burn. A stable metric level confirms the company's financial stability until new strategic investments are secured.

Analysis of competing companies

TEM (Tempus AI Inc) - Cash Calculated per Single Share|Cash per Share QGEN|IONS - Cash on Hand per Share|Cash Funds per Share Repligen RGEN|RNA: Cash Funds per Single Share|CRSP: Cash per Single Share|GeneDx Corp (WGS) - Cash per Single Share|RARE: Cash per Share|BEAM - Cash Funds Calculated per Share|SRPT (Sarepta Therapeutics) - Cash per Share|Cash per Single Share Twist Bioscience Inc (TWST)|Cash per Share TXG|Cash Funds Calculated per Share Intellia|Stoke - Cash per Single Share|BLFS: Cash Funds per Single Share|Wave Life Sciences Corp - Cash per Share|Maze Therapeutics, Inc. (MAZE) - Cash per Single Share|Sionna Therapeutics Inc (SION) - Cash Funds per Share|Cash per Single Share Prime Medicine Corp|Cash Funds per Share tayshagtx.com|QURE - Cash Funds Volume per Share|Cash per Single Share MGTX (MeiraGTx Holdings plc)|REGENXBIO (RGNX) - Cash Funds Volume per Share|Cash per Share SLDB (Solid Biosciences Inc.)|Amount of Cash per Share OCGN|PacBio Corp - Cash per Share|Benitec Biopharma Inc. (BNTC) - Cash per Single Share|DSGN: Cash per Share|Cash Funds per Single Share RCKT|Cash per Single Share FDMT|Cash Funds per Single Share LXEO (Lexeo Therapeutics)|Cash per Share KRRO|Editas Medicine, Inc. - Cash Funds per Single Share|Cash Funds per Share Silence Therapeutics Inc. SLN|Cash per Share ProQR Therapeutics N.V. PRQR|CDXS: Cash per Single Share|Cash Funds Volume per Share Sangamo (SGMO)|NAUT (Nautilus Bio) - Cash per Single Share|MGX - Cash Funds Calculated per Share|DTIL (Precision BioSciences Inc.) - Cash per Share|generationbio.com (GBIO) - Cash Funds Calculated per Share|Cash Funds per Share Boundless Bio Inc (BOLD)|Cash per Share Exicure Inc. (XCUR)|Cash Funds per Share imunon.com IMNN|Amount of Cash per Share MBIO|RNAZ - Cash Funds per Share|Amount of Cash per Share BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Cash Funds per Share|Bluebird Bio - Amount of Cash per Share|IPA (ImmunoPrecise Antibodies Ltd) - Cash per Share|Cash on Hand per Share Omega Therapeutics, Inc. OMGA|Cash per Share OMIC|RGLS (Regulus Therapeutics Inc.) - Amount of Cash per Share|Cash per Share SYRS (Syros Pharmaceuticals Inc.)|Cash Calculated per Single Share TBIO (Codex DNA)|TCON - Cash Funds per Share|Cash on Hand per Share Unity Biotechnology